Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes

导出原文传递

翻译打印收藏纠错

作者： Haering, Hans-Ulrich ^[1] ; Merker, Ludwig ^[2] ; Christiansen, Anita Vedel ^[3] ; Roux, Flavien ^[4] ; Salsali, Afshin ^[5] ; Kim, Gabriel ^[6] ; Meinicke, Thomas ^[7] ; Woerle, Hans J. ; Broedl, Uli C.

作者单位： Boehringer Ingelheim Pharma GmbH & Co KG, D-55216 Ingelheim, Germany ^[1] Boehringer Ingelheim Reims SAS, F-51100 Reims, France ^[2] Boehringer Ingelheim Pharma GmbH & Co KG, D-88397 Biberach, Germany ^[3] Diabet & Nierenzentrum, D-41540 Dormagen, Germany ^[4] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06788 USA ^[5] Boehringer Ingelheim Danmark AS, DK-2100 Copenhagen, Denmark ^[6] Univ Tubingen, Dept Internal Med 4, D-72076 Tubingen, Germany ^[7]

关键词 Empagliflozin Glycaemic control Metformin SGLT2 inhibitor Sulphonylurea

发布时间 2017-04-05

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交